🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,063 results for “BRIGHT MINDS BIOSCIENCES INC.” Clear

  1. Antiretroviral therapy (ART)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infection

    approved small molecule completed

    1 trial

  2. Athena strategy

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    approved other active

    1 trial

  3. Atomoxetine hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit Disorder With Hyperactivity

    approved small molecule completed

    1 trial

  4. BUP microdose induction

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    approved small molecule terminated

    1 trial

  5. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    approved other completed

    2 trials

  6. Behavioral Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    approved other completed

    1 trial

  7. Behavioral: Buprenorphine/naloxone maintenance (Mtn)

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    approved other completed

    1 trial

  8. Bleomycin

    BRIGHT MINDS BIOSCIENCES INC.

    Keloid

    approved small molecule active

    1 trial

  9. Brand lamotrigine

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    approved small molecule completed

    1 trial

  10. Brixadi (Injectable Buprenorphine)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    approved small molecule active

    1 trial

  11. Buccal Buprenorphine 300 mcg

    BRIGHT MINDS BIOSCIENCES INC.

    Analgesia

    approved small molecule active

    1 trial

  12. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    approved small molecule completed

    28 trials

  13. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate-related Disorders

    approved small molecule completed

    1 trial

  14. Buprenorphine/naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    approved small molecule completed

    2 trials

  15. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit Hyperactivity Disorder

    approved small molecule completed

    1 trial

  16. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    approved small molecule completed

    2 trials

  17. Bupropion Extended Release Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Postpartum Smoking Relapse

    approved small molecule active

    1 trial

  18. Bupropion SR

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    approved small molecule completed

    2 trials

  19. Buspirone

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    approved small molecule completed

    1 trial

  20. Carbamazepine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    approved small molecule completed

    4 trials

  21. Cefepime, Meropenem, or Piperacillin/Tazobactam

    BRIGHT MINDS BIOSCIENCES INC.

    Pneumonia

    approved small molecule terminated

    1 trial

  22. Clozapine

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    approved small molecule completed

    1 trial

  23. Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    approved small molecule completed

    4 trials

  24. Cocaine-Related Disorders

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    approved small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources